Application of cd317 protein in prevention and treatment of viral infection

Abstract

The invention discloses the use of CD317 in preventing and / or treating human herpes virus 6 (human herpes virus 6, HHV-6) infection. By constructing an expression vector expressing the human CD317 gene and further constructing host cells with up-regulated CD317 expression, the HHV-6 virus strain was infected with the host cells with up-regulated CD317 expression, and then the expression level of the early stage protein IE1 and changes in viral productivity were detected. Compared with the Control group, the up-regulation of CD317 expression can significantly reduce the expression of the early stage protein IE1 and reduce the total virus production, indicating that the CD317 protein can significantly inhibit the proliferation of HHV-6 virus and reduce the invasion of HHV-6 virus into infected host cells. The HHV-6 viral activity can be used to prepare a medicament for preventing and / or treating HHV-6 infection.

Description

technical field [0001] The invention belongs to the field of biotechnology, and relates to the application of CD317 protein in preventing and treating viral infection, in particular to the application of CD317 protein in preparing medicine for preventing and / or treating HHV-6 infection. Background technique [0002] Human herpes virus 6 (human herpes virus 6, HHV-6) belongs to the beta subtype of human herpes virus, which is a kind of double-stranded DNA virus that is addicted to human T lymphocytes. The infection is very common in the population, and the positive rate of HHV-6 antibody in the Asian population is more than 90%. Primary infection of HHV-6 generally occurs in infants and young children aged 6 months to 2 years, and the peak period is 6-9 months, and then long-term latent infection is established in brain tissue, monocytes or macrophages. A pathogen that causes acute rash in infants and young children. HHV-6 can be reactivated or re-infected when the body's i...

AI Technical Summary

Problems solved by technology

[0005] Although CD317 can inhibit the exit of various enveloped viruses through its special topological structure, it can inhibit human immunodeficiency virus type 1 (Human immunodeficiency virus 1, HIV-1), influenza virus type A (FluA), Ebola virus (Ebola virus virus), human immunodeficiency virus type 2 (Human immunodeficiency virus 2, HIV-2), Japanese encephalitis virus (Japanese encephalitis virus), Sendai virus (Sendai virus), human herpes virus α subtype herpes simplex virus type 1 ( Herpes simplex virus 1, HSV-1) and herpes simplex virus 2 (Herpessimple virus 2, HSV-2), Kaposi's Sarcoma-Associated Herpesvirus (KSHV) in the human herpesvirus gamma subtype , coronavirus (coronavirus229E) and other enveloped viruses have the effect of inhibiting infection, but existing studies have shown that CD317 does not have the effect of inhibiting infection for all enveloped viruses

Images